Herbert Smith Freehills (London)

Ruth Allen

Herbert Smith Freehills (London)
Professional support lawyer

Ruth is a professional support lawyer in the competition, regulation and trade practice at Herbert Smith Freehills LLP, based in London. She provides technical advice to clients and colleagues on issues of both substantive competition law and procedure, and is also responsible for know-how resources and training programmes. Ruth previously worked as an associate in the team, and has a wide range of both contentious and non-contentious experience across all aspects of EU and UK competition law. She has a particular interest in competition litigation and foreign direct investment regulation.

Distinctions

Auteurs associés

Herbert Smith Freehills (London)
Herbert Smith Freehills (Johannesburg)
Herbert Smith Freehills (London)
Herbert Smith Freehills (London)
Herbert Smith Freehills (Brussels)

Articles

3034 Bulletin

Emily Barry, Helen Beatty, John Chetwood, Veronica Roberts, Ruth Allen The UK Parliament welcomes the National Security and Investment Act to review transactions on national security grounds, and potentially prohibit their completion or require remedies to allow them to proceed

223

On 29 April 2021 the National Security and Investment (NSI) Bill received Royal Assent. The NSI Act 2021 introduces significant legislative reforms which will overhaul the ability of the UK Government to review transactions on national security grounds, and potentially prohibit their completion (...)

Stephen Wisking, Kim Dietzel, Andrew North, Ruth Allen The UK Supreme Court overturns a Competition Appeal Tribunal’s ruling and clarifies the class action regime in a proceeding brought against a credit card company (Merricks / Mastercard)

147

Earlier today the Supreme Court handed down its hotly-anticipated judgment regarding the certification of an opt-out competition collective action brought by Walter Merricks against Mastercard. The claim is seeking £14bn in damages on behalf of some 46.2 million UK consumers, in respect of (...)

Daniel Woods, Stephen Wisking, Kim Dietzel, Ruth Allen The UK Supreme Court hands down a significant judgment relating to the certification of a £14bn opt-out competition collective action brought against a credit card company (Merricks / Mastercard)

114

On 11 December 2020 the Supreme Court handed down a very significant judgment relating to the certification of a £14bn opt-out competition collective action brought by Walter Merricks against Mastercard, in respect of losses alleged to have resulted from the use of anti-competitive multilateral (...)

Veronica Roberts, Daniel Vowden, Ruth Allen, Kristien Geeurickx The UK Competition Authority announces its provisional clearance of a proposed acquisition of a stake in a food delivery company in its first application of “failing firm” defence during the COVID-19 pandemic (Amazon / Deliveroo)

1596

On 17 April 2020 the CMA announced its provisional clearance of Amazon’s proposed acquisition of a stake in Deliveroo. The transaction was referred for an in-depth Phase 2 investigation in December 2019, in light of concerns about the impact on competition for the supply of online restaurant (...)

Ruth Allen, Kyriakos Fountoukakos, Stephen Wisking The UK Court of Appeal seeks to reinstate record fines totalling £89.4million imposed on pharmaceutical companies for abuse of dominant position through excessive and unfair pricing of an anti-epilepsy drug (Pfizer / Flynn)

222

On 10 March 2020 the UK Court of Appeal handed down its hotly anticipated judgment in Flynn Pharma Limited & Anr vs Competition and Markets Authority. The UK Competition and Markets Authority (CMA) was seeking to reinstate record fines totalling £89.4m imposed on pharmaceutical companies (...)

Kyriakos Fountoukakos, Dafni Katrana, Ruth Allen The EU Court of Justice clarifies the criteria for the pay-for-delay agreements in the pharmaceutical sector (Generics - UK / GlaxoSmithKline / Actavis / Xellia Pharmaceuticals / Merck / Alpharma)

335

On 30 January 2020 the European Court of Justice (“ECJ”) clarified for the first time the criteria governing whether so-called “pay-for-delay” agreements entered into between originator and generic pharmaceutical companies fall foul of EU competition law rules. Such agreements are a form of patent (...)

Envoyer un message